Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Conditions:   Oral Squamous Cell Carcinoma;   Oropharyngeal Squamous Cell Carcinoma Interventions:   Drug: Tislelizumab;   Drug: Albumin-Bound Paclitaxel;   Drug: Cisplatin Sponsor:   Peking University Hospital of Stomatology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials